Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis

被引:31
作者
Goldfarb, RD
Parker, TS
Levine, DM
Glock, D
Akhter, I
Alkhudari, A
McCarthy, RJ
David, EM
Gordon, BR
Saal, SD
Rubin, AL
Trenholme, GM
Parrillo, JE
机构
[1] Rush Med Coll, Sect Crit Care Med, Chicago, IL 60612 USA
[2] Rush Med Coll, Infect Dis Sect, Chicago, IL 60612 USA
[3] New York Hosp, Cornell Med Ctr, Rogosin Inst, New York, NY 10021 USA
[4] New York Hosp, Cornell Med Ctr, Dept Biochem, New York, NY 10021 USA
[5] New York Hosp, Cornell Med Ctr, Dept Surg, New York, NY 10021 USA
关键词
serum endotoxin; tumor necrosis factor; cardiac contractility; cardiac output; lipoprotein;
D O I
10.1152/ajpregu.00285.2002
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Lipoprotein phospholipid (PL) plays a major role in neutralization of endotoxin. This study tested the hypothesis that prophylactic administration of a PL-enriched emulsion (PRE), which augments PL content of serum lipoproteins and neutralizes endotoxin in vitro, would preserve cardiovascular function and improve survival in porcine septic peritonitis. A control group was compared with low-, mid-, and high- dose treatment groups that received PRE by primed continuous infusion for 48 h. A fibrin clot containing live Escherichia coli 0111.B4 was implanted intraperitoneally 30 min after the priming dose. Survival increased in a dose-dependent manner and was correlated with serum PL. Infused PL was associated with high- density lipoprotein in the low- dose group and all serum lipoproteins at higher doses. Treatment significantly lowered serum endotoxin and tumor necrosis factor (TNF)-alpha, preserved cardiac output and ejection fraction, and attenuated increases in systemic and pulmonary vascular resistances. This study demonstrated that augmentation of lipoprotein PL via administration of PRE improved survival and offered a novel therapeutic approach to sepsis.
引用
收藏
页码:R550 / R557
页数:8
相关论文
共 38 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] STUDIES WITH RADIOACTIVE ENDOTOXIN .3. EFFECT OF TOLERANCE ON THE DISTRIBUTION OF RADIOACTIVITY AFTER INTRAVENOUS INJECTION OF ESCHERICHIA-COLI ENDOTOXIN LABELED WITH CR51
    CAREY, FJ
    BRAUDE, AI
    ZALESKY, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1958, 37 (03) : 441 - 457
  • [3] FREUDENBERG MA, 1980, INFECT IMMUN, V28, P373
  • [4] Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock
    Goldfarb, RD
    Glock, D
    Johnson, K
    Creasey, AA
    Carr, C
    McCarthy, RJ
    Matushek, M
    Akhter, I
    Trenholme, G
    Parrillo, JE
    [J]. SHOCK, 1998, 10 (04): : 258 - 264
  • [5] A porcine model of peritonitis and bacteremia simulates human septic shock
    Goldfarb, RD
    Glock, D
    Kumar, A
    McCarthy, RJ
    Mei, J
    Guynn, T
    Matushek, M
    Trenholme, G
    Parrillo, JE
    [J]. SHOCK, 1996, 6 (06): : 442 - 451
  • [6] Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia
    Gordon, BR
    Parker, TS
    Levine, DM
    Saal, SD
    Wang, JCL
    Sloan, BJ
    Barie, PS
    Rubin, AL
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (04) : 584 - 589
  • [7] CHOLESTASIS - LAMELLAR STRUCTURE OF ABNORMAL HUMAN SERUM LIPOPROTEIN
    HAMILTON, RL
    HAVEL, RJ
    KANE, JP
    BLAUROCK, AE
    SATA, T
    [J]. SCIENCE, 1971, 172 (3982) : 475 - &
  • [8] CHYLOMICRONS ALTER THE FATE OF ENDOTOXIN, DECREASING TUMOR-NECROSIS-FACTOR RELEASE AND PREVENTING DEATH
    HARRIS, HW
    GRUNFELD, C
    FEINGOLD, KR
    READ, TE
    KANE, JP
    JONES, AL
    EICHBAUM, EB
    BLAND, GF
    RAPP, JH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) : 1028 - 1034
  • [9] HUBSCH AP, 1993, CIRC SHOCK, V40, P14
  • [10] Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases
    Iribarren, C
    Jacobs, DR
    Sidney, S
    Claxton, AJ
    Feingold, KR
    [J]. EPIDEMIOLOGY AND INFECTION, 1998, 121 (02) : 335 - 347